In combination w/ at least 2 other antiretroviral agents for the management of HIV infected adults. Treatment of chronic hepatitis B in adults w/ compensated liver disease, w/ evidence of active viral replication, persistent elevated serum ALT level & histological evidence of active inflammation & fibrosis.
Adult HIV or chronic hepatitis B 300 mg once daily. Renal impairment CrCl ≥50 mL/min 300 mg every 24 hr, 30-49 mL/min 300 mg every 48 hr, 10-29 mL/min 300 mg every 72-96 hr. Hemodialysis patient 300 mg every 7 days or after a total of approx 12 hr of dialysis.
Lactic acidosis & severe hepatomegaly w/ steatosis & severe acute exacerbations of hepatitis. Not proven to prevent the risk of transmission of HIV or HBV through sexual contact or blood contamination. Opportunistic infection & other HIV complications may develop. Patients w/ cirrhosis; preexisting liver dysfunction including chronic active hepatitis. Suspend treatment if lactic acidosis & hepatotoxicity develops. Observe for evidence of bone abnormalities; lipodystrophy; inflammatory symptoms; joint aches/pain, joint stiffness or difficulty in movement. Routine monitoring for changes in serum creatinine & P. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Decreased hepatic, renal or cardiac function. Use of effective contraception in women of childbearing potential. Pregnancy. Do not use during lactation. Elderly.
Caution when in combination w/ didanosine. Affected pharmacokinetics of atazanavir. High rates of virological failure & emergence of resistance at early stage in HIV patients w/ lamivudine, abacavir & didanosine. Increased serum conc w/ tacrolimus or other drugs affecting renal function. Risk of development of HIV resistance in combination regimen in HIV/HBV con-infected patients.
J05AF07 - tenofovir disoproxil ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Sign Out
